Shopping Cart

Your shopping cart is currently empty

Tanzisertib

Name: Tanzisertib
Brand: TargetMol
SKU: T14895
Price: 35 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Hot

Catalog No. T14895Cas No. 899805-25-5

Alias CC-930

Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.

Tanzisertib

😃Good

Hot

Purity: 99.28%

Catalog No. T14895Alias CC-930Cas No. 899805-25-5

Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$35	In Stock	In Stock
5 mg	$89	In Stock	In Stock
10 mg	$148	In Stock	In Stock
25 mg	$297	In Stock	In Stock
50 mg	$588	In Stock	In Stock
100 mg	$783	In Stock	In Stock
200 mg	$1,080	-	In Stock
1 mL x 10 mM (in DMSO)	$88	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.28%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.
Targets&IC50	JNK2:7 nM, JNK1:61 nM, JNK3:6 nM
In vitro	Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1] and blocks the JNK pathway activated by pro-fibrotic cytokines in systemic sclerosis[3]. Tanzisertib (CC-930) (1-2 μM) substantially reduces and abrogates apoptosis and necrosis in hepatocytes, including FC-loaded WT hepatocytes[2].
In vivo	Tanzisertib (CC-930), when administered orally at doses of 10 and 30 mg/kg, decreases TNFa production by 23% and 77% respectively in the acute rat LPS-induced TNFa production PK-PD model[1]. Additionally, at a dose of 150 mg/kg, Tanzisertib (CC-930) not only prevents the development of fibrosis across various models but also reverses pre-existing fibrosis[3].
Synonyms	CC-930

Chemical Properties

Molecular Weight	448.44
Formula	C₂₁H₂₃F₃N₆O₂
Cas No.	899805-25-5
Smiles	N(C=1N(C=2C(N1)=CN=C(N[C@H]3CC[C@H](O)CC3)N2)[C@H]4CCOC4)C5=C(F)C=C(F)C=C5F
Relative Density.	1.63 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

1M HCl: 100 mg/mL (223 mM)

DMSO: 250 mg/mL (557.49 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.46 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

1M HCl/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2300 mL	11.1498 mL	22.2995 mL	111.4976 mL
5 mM	0.4460 mL	2.2300 mL	4.4599 mL	22.2995 mL
10 mM	0.2230 mL	1.1150 mL	2.2300 mL	11.1498 mL
20 mM	0.1115 mL	0.5575 mL	1.1150 mL	5.5749 mL
50 mM	0.0446 mL	0.2230 mL	0.4460 mL	2.2300 mL
100 mM	0.0223 mL	0.1115 mL	0.2230 mL	1.1150 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc